A Randomized Clinical Trial in Patients With a Pedophilic Disorder

Briken, Peer

doi:10.1001/jamapsychiatry.2020.0430

Cited by 2 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was found to reduce the risk score of committing sexual abuse in men with paedophilic disorder 2 weeks after the initial injection. This study was considered to be a milestone (Briken 2020). Both studies, however, relied on outcome measures with very limited validation, especially given the reliance on self-report from a forensic population where such a report can be unreliable.…”

Section: Commentary On Guidelines For the Pharmacological Treatment Omentioning

confidence: 99%

Commentary on guidelines for the pharmacological treatment of paraphilic disorders

Krueger

2020

The World Journal of Biological Psychiatry

View full text Add to dashboard Cite

Section: Commentary On Guidelines For the Pharmacological Treatment Omentioning

confidence: 99%

Commentary on guidelines for the pharmacological treatment of paraphilic disorders

Krueger

2020

The World Journal of Biological Psychiatry

View full text Add to dashboard Cite

Survey on the Prescription Patterns of Pharmacological Agents in Individuals Who Have Committed Sexual Offenses During Forensic Outpatient Treatment in Germany: How Many Discontinue Testosterone Lowering Medication Under Parole?

Sauter

Rettenberger

Briken

et al. 2022

The Journal of Sexual Medicine

View full text Add to dashboard Cite

Background The number of individuals who sexually offended, and who are continued to be treated with pharmacological agents to reduce sex drive after their release from prison or forensic psychiatry, are not known. Furthermore, figures on the number of those who stop their sexdrive supressing antiandrogen treatment in the outpatient setting are unknown as well. This is of central importance though as it might be associated with an increased risk of recidivism. Aim To assess prescription patterns as well as adherence to pharmacological treatment in outpatient clinics in Germany for individuals who have sexually offended and were released from prison or forensic psychiatric hospital. Methods A self-constructed online survey assessing the pharmacological treatment modalities was sent by e-mail to n = 103 forensic outpatient clinics in Germany. Thirty-three (32.0%) completed the questionnaire and reported about 834 patients. Outcomes Prevalence of the use of different pharmacological agents in the treatment of individuals convicted for sexual offenses as well as the number of patients who have discontinued testosterone-lowering medication (TLM). Results Among all institutions, 22.4% (n = 187) of individuals received pharmacological treatment, with 40.1% receiving gonadotropin-releasing-hormone-agonists, 26.2% antipsychotics, 24.6% selective serotonin reuptake inhibitors, 6.4% cyproterone acetate, and 2.7% a combination of gonadotropin-releasing-hormone-agonists and cyproterone acetate. A significant positive correlation was found between the number of patients released from a forensic-psychiatric hospital and the number of patients treated with TLM. Within 1 year 8.6% (n = 16) stopped their TLM during or at the end of the supervision period, most of them against treatment providers advice. Clinical Implications Substantial regional differences indicate uncertainties regarding the prescription of pharmacological agents for outpatients who have committed sexual offences in Germany. The discontinuiation of TLM within the first year of treatment against treatment providers advise in a substantial proportion of patients could be associated with a serious risk for reoffending. Strengths & Limitations The present survey captures prevalences of the pharmacotherapy in forensic aftercare facilities for individuals who have offended sexually, and is the first to record the number of discontinuations. This is a cross-sectional survey covering only 1 country, but includes a large number of individuals. Conclusion Even though the number of treated individuals has increased in prisons, the majority of pharmacological treatment is still provided by forensic hospitals, which then translates into the outpatient setting. The number of those who stop taking such medication is a highly relevant topic for both forensic treatment providers and legal decision makers

show abstract

A Randomized Clinical Trial in Patients With a Pedophilic Disorder

Cited by 2 publications

References 9 publications

Commentary on guidelines for the pharmacological treatment of paraphilic disorders

Commentary on guidelines for the pharmacological treatment of paraphilic disorders

Survey on the Prescription Patterns of Pharmacological Agents in Individuals Who Have Committed Sexual Offenses During Forensic Outpatient Treatment in Germany: How Many Discontinue Testosterone Lowering Medication Under Parole?

Contact Info

Product

Resources

About